The DOI matches its Crossref record; 227 of the 227 references it cites were found in a registry or an index.
Molecular mechanisms of chemo‐ and radiotherapy resistance and the potential implications for cancer treatment
Open accessAbstract
Cancer is a leading cause of death worldwide. Surgery is the primary treatment approach for cancer, but the survival rate is very low due to the rapid progression of the disease and presence of local and distant metastasis at diagnosis. Adjuvant chemotherapy and radiotherapy are important components of the multidisciplinary approaches for cancer treatment. However, resistance to radiotherapy and chemotherapy may result in treatment failure or even cancer recurrence. Radioresistance in cancer is often caused by the repair response to radiation‐induced DNA damage, cell cycle dysregulation, cancer stem cells (CSCs) resilience, and epithelial‐mesenchymal transition (EMT). Understanding the molecular alterations that lead to radioresistance may provide new diagnostic markers and therapeutic targets to improve radiotherapy efficacy. Patients who develop resistance to chemotherapy drugs cannot benefit from the cytotoxicity induced by the prescribed drug and will likely have a poor outcome with these treatments. Chemotherapy often shows a low response rate due to various drug resistance mechanisms. This review focuses on the molecular mechanisms of radioresistance and chemoresistance in cancer and discusses recent developments in therapeutic strategies targeting chemoradiotherapy resistance to improve treatment outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Chen, Y., Zhang, F., Tsai, Y., Yang, X., Li, Y., Duan, S., Wang, X., Keng, P., & Lee, S. O. (2015) · Radiation Oncology · doi:10.1186/s13014-015-0534-1 · Cited by 79
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Bao, S., Wu, Q., McLendon, R. E., Hao, Y., Shi, Q., Hjelmeland, A. B., Dewhirst, M. W., Bigner, D. D., & Rich, J. N. (2006) · Nature · doi:10.1038/nature05236 · Cited by 6,379
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092
The resurgence of platinum-based cancer chemotherapy
Kelland, L. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2167 · Cited by 4,717
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760 · cited 4×
“149 156 Ovarian cancer patients with normal expression of wild-type p53 have been reported to be more likely to achieve good cisplatin outcomes than patients with p53 mutations.”
InfluentialEnzinger, P. C., & Mayer, R. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmra035010 · Cited by 2,509
Johnstone, T. C., Suntharalingam, K., & Lippard, S. J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00597 · Cited by 2,485
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
EGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Poly(ADP-ribose): novel functions for an old molecule
Schreiber, V., Dantzer, F., Ame, J.-C., & de Murcia, G. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1963 · Cited by 1,915
The Different Mechanisms of Cancer Drug Resistance: A Brief Review
Mansoori, B., Mohammadi, A., Davudian, S., Shirjang, S., & Baradaran, B. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.041 · Cited by 1,883
Florea, A.-M., & Büsselberg, D. (2011) · Cancers · doi:10.3390/cancers3011351 · Cited by 1,759
DNA repair pathways as targets for cancer therapy
Helleday, T., Petermann, E., Lundin, C., Hodgson, B., & Sharma, R. A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2342 · Cited by 1,666
Ionizing radiation-induced metabolic oxidative stress and prolonged cell injury
Azzam, E. I., Jay-Gerin, J.-P., & Pain, D. (2012) · Cancer Letters · doi:10.1016/j.canlet.2011.12.012 · Cited by 1,553
DNA Damage Sensing by the ATM and ATR Kinases
Marechal, A., & Zou, L. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012716 · Cited by 1,514
Amé, J., Spenlehauer, C., & de Murcia, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,459
Wold, M. S. (1997) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.66.1.61 · Cited by 1,444
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M.-H., & Hung, M.-C. (2001) · Nature Cell Biology · doi:10.1038/35060032 · Cited by 1,135
Sensing and repairing DNA double-strand breaks
Jackson, S. P. (2002) · Carcinogenesis · doi:10.1093/carcin/23.5.687 · Cited by 1,128
Drug resistance and combating drug resistance in cancer
Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,085
Ras in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
5-Fluorouracil: Mechanisms of Resistance and Reversal Strategies
Zhang, N., Yin, Y., Xu, S.-J., & Chen, W.-S. (2008) · Molecules · doi:10.3390/molecules13081551 · Cited by 771
Shen, M.-L., Jones, I. M., & Mohrenweiser, H. W. (1998) · PubMed · Cited by 769
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Wieduwilt, M. J., & Moasser, M. M. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-7440-8 · Cited by 751
Survival of the Fittest: Cancer Stem Cells in Therapeutic Resistance and Angiogenesis
Eyler, C. E., & Rich, J. N. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.1829 · Cited by 737
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Mechanisms of Multidrug Resistance in Cancer
Gillet, J.-P., & Gottesman, M. M. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-416-6_4 · Cited by 685
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Alfarouk, K. O., Stock, C.-M., Taylor, S., Walsh, M., Muddathir, A. K., Verduzco, D., Bashir, A. H. H., Mohammed, O. Y., Elhassan, G. O., Harguindey, S., et al. (2015) · Cancer Cell International · doi:10.1186/s12935-015-0221-1 · Cited by 665
Cyclin D1, cancer progression, and opportunities in cancer treatment
Qie, S., & Diehl, J. A. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1475-3 · Cited by 657
WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells
Woodward, W. A., Chen, M. S., Behbod, F., Alfaro, M. P., Buchholz, T. A., & Rosen, J. M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606599104 · Cited by 603
Targeting Microtubules by Natural Agents for Cancer Therapy
Mukhtar, E., Adhami, V. M., & Mukhtar, H. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0791 · Cited by 565
Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer
Lambert, J. M., & Chari, R. V. J. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500766w · Cited by 545
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494
p21 and p27: roles in carcinogenesis and drug resistance
Abukhdeir, A. M., & Park, B. H. (2008) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399408000744 · Cited by 463
Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance
Chang, J. C. (2016) · Medicine · doi:10.1097/md.0000000000004766 · Cited by 435
Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism
Peters, G. J., Backus, H. H. J., Freemantle, S., van Triest, B., Codacci-Pisanelli, G., van der Wilt, C. L., Smid, K., Lunec, J., Calvert, A. H., Marsh, S., et al. (2002) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(02)00082-0 · Cited by 420
Stemness in Cancer: Stem Cells, Cancer Stem Cells, and Their Microenvironment
Aponte, P. M., & Caicedo, A. (2017) · Stem Cells International · doi:10.1155/2017/5619472 · Cited by 375
ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer
Friboulet, L., Olaussen, K. A., Pignon, J.-P., Shepherd, F. A., Tsao, M.-S., Graziano, S., Kratzke, R., Douillard, J.-Y., Seymour, L., Pirker, R., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214271 · Cited by 371
Medical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 370
Cisplatin resistance: Preclinical findings and clinical implications
Köberle, B., Tomicic, M. T., Usanova, S., & Kaina, B. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.07.004 · Cited by 361
Trastuzumab‐associated cardiotoxicity
Keefe, D. L. (2002) · Cancer · doi:10.1002/cncr.10854 · Cited by 358
Samimi, G., Safaei, R., Katano, K., Holzer, A. K., Rochdi, M., Tomioka, M., Goodman, M., & Howell, S. B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0137 · Cited by 358
Cell-Cycle Therapeutics Come of Age
Ingham, M., & Schwartz, G. K. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.0032 · Cited by 353
Kim, I.-M., Ackerson, T., Ramakrishna, S., Tretiakova, M., Wang, I.-C., Kalin, T. V., Major, M. L., Gusarova, G. A., Yoder, H. M., Costa, R. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3003 · Cited by 337
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance
Martinez-Balibrea, E., Martínez-Cardús, A., Ginés, A., Ruiz de Porras, V., Moutinho, C., Layos, L., Manzano, J. L., Bugés, C., Bystrup, S., Esteller, M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0636 · Cited by 335
Checkpoint Protein BubR1 Acts Synergistically with Mad2 to Inhibit Anaphase-promoting Complex
Fang, G. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.01-09-0437 · Cited by 330
Ionizing radiation-induced DNA injury and damage detection in patients with breast cancer
Borrego-Soto, G., Ortiz-López, R., & Rojas-Martínez, A. (2015) · Genetics and Molecular Biology · doi:10.1590/s1415-475738420150019 · Cited by 320
The human mitotic checkpoint protein BubR1 regulates chromosome–spindle attachments
Lampson, M. A., & Kapoor, T. M. (2005) · Nature Cell Biology · doi:10.1038/ncb1208 · Cited by 311
FoxM1: A Master Regulator of Tumor Metastasis
Raychaudhuri, P., & Park, H. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0640 · Cited by 308
Chang, L., Graham, P. H., Hao, J., Ni, J., Bucci, J., Cozzi, P. J., Kearsley, J. H., & Li, Y. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.415 · Cited by 304
ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair
Ahmad, A., Robinson, A. R., Duensing, A., van Drunen, E., Beverloo, H. B., Weisberg, D. B., Hasty, P., Hoeijmakers, J. H. J., & Niedernhofer, L. J. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00293-08 · Cited by 299
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistance
Wang, S., Song, Y., & Liu, D. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.11.008 · Cited by 293
The JAK2/STAT3/CCND2 Axis promotes colorectal Cancer stem cell persistence and radioresistance
Park, S.-Y., Lee, C.-J., Choi, J.-H., Kim, J.-H., Kim, J.-W., Kim, J.-Y., & Nam, J.-S. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1405-7 · Cited by 292
Enhancing Tumor-Specific Uptake of the Anticancer Drug Cisplatin with a Copper Chelator
Ishida, S., McCormick, F., Smith-McCune, K., & Hanahan, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.04.011 · Cited by 288
Clinical Cardiac Tolerability of Trastuzumab
Perez, E. A., & Rodeheffer, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.120 · Cited by 280
Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases
Chen, Z., & Tiwari, A. K. (2011) · The FEBS Journal · doi:10.1111/j.1742-4658.2011.08235.x · Cited by 274
Autophagy contributes to resistance of tumor cells to ionizing radiation
Chaachouay, H., Ohneseit, P., Toulany, M., Kehlbach, R., Multhoff, G., & Rodemann, H. P. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.06.002 · Cited by 264
Noordhuis, P., Holwerda, U., Van der Wilt, C. L., Van Groeningen, C. J., Smid, K., Meijer, S., Pinedo, H. M., & Peters, G. J. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh264 · Cited by 264
Chang, B. Y., Conroy, K. B., Machleder, E. M., & Cartwright, C. A. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.6.3245 · Cited by 260
Multidrug resistance: Physiological principles and nanomedical solutions
Kunjachan, S., Rychlik, B., Storm, G., Kiessling, F., & Lammers, T. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.018 · Cited by 259
Koike, K., Kawabe, T., Tanaka, T., Toh, S., Uchiumi, T., Wada, M., Akiyama, S. I., Ono, M., & Kuwano, M. (1997) · PubMed · Cited by 249
Biological effects of radiation on cancer cells
Wang, J.-S., Wang, H.-J., & Qian, H.-L. (2018) · Military Medical Research · doi:10.1186/s40779-018-0167-4 · Cited by 244
(1992) · Lung Cancer · doi:10.1016/0169-5002(92)90185-m · Cited by 237
Gomez-Casal, R., Bhattacharya, C., Ganesh, N., Bailey, L., Basse, P., Gibson, M., Epperly, M., & Levina, V. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-94 · Cited by 225
Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents
Fojo, T., & Menefee, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm172 · Cited by 217
Rich, T. A., Shepard, R. C., & Mosley, S. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.009 · Cited by 212
Oliver, T. G., Mercer, K. L., Sayles, L. C., Burke, J. R., Mendus, D., Lovejoy, K. S., Cheng, M.-H., Subramanian, A., Mu, D., Powers, S., et al. (2010) · Genes & Development · doi:10.1101/gad.1897010 · Cited by 210
Radiation-induced signaling pathways that promote cancer cell survival (Review)
HEIN, A. L., OUELLETTE, M. M., & YAN, Y. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2614 · Cited by 201
Wang, S., Tsui, S. T., Liu, C., Song, Y., & Liu, D. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0290-1 · Cited by 194
Pharmacology of free radicals and the impact of reactive oxygen species on the testis.
Aprioku, J. S. (2013) · PubMed Central · Cited by 191
Recent Advances in p53 Research and Cancer Treatment
Suzuki, K., & Matsubara, H. (2011) · BioMed Research International · doi:10.1155/2011/978312 · Cited by 188
Sandur, S. K., Deorukhkar, A., Pandey, M. K., Pabón, A. M., Shentu, S., Guha, S., Aggarwal, B. B., & Krishnan, S. (2009) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2009.06.034 · Cited by 183
Downregulation of XPF–ERCC1 enhances cisplatin efficacy in cancer cells☆
Arora, S., Kothandapani, A., Tillison, K., Kalman-Maltese, V., & Patrick, S. M. (2010) · DNA Repair · doi:10.1016/j.dnarep.2010.03.010 · Cited by 182
Structural basis for the recruitment of ERCC1‐XPF to nucleotide excision repair complexes by XPA
Tsodikov, O. V., Ivanov, D., Orelli, B., Staresincic, L., Shoshani, I., Oberman, R., Schärer, O. D., Wagner, G., & Ellenberger, T. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601894 · Cited by 167
Palbociclib: First Global Approval
Dhillon, S. (2015) · Drugs · doi:10.1007/s40265-015-0379-9 · Cited by 165
Liu, J., Xue, N., Guo, Y., Niu, K., Gao, L., Zhang, S., Gu, H., Wang, X., Zhao, D., & Fan, R. (2019) · Aging · doi:10.18632/aging.102580 · Cited by 159
Thymidylate Synthase: A Critical Target for Cancer Chemotherapy
Rose, M. G., Farrell, M. P., & Schmitz, J. C. (2002) · Clinical Colorectal Cancer · doi:10.3816/ccc.2002.n.003 · Cited by 151
Nakayama, K., Kanzaki, A., Ogawa, K., Miyazaki, K., Neamati, N., & Takebayashi, Y. (2002) · International Journal of Cancer · doi:10.1002/ijc.10608 · Cited by 145
Targeting inflammatory pathways for tumor radiosensitization
Deorukhkar, A., & Krishnan, S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.039 · Cited by 144
Abrogation of radioresistance in glioblastoma stem‐like cells by inhibition of ATM kinase
Carruthers, R., Ahmed, S. U., Strathdee, K. E., Gomez-Roman, N., Amoah-Buahin, E., Watts, C., & Chalmers, A. J. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.08.003 · Cited by 143
Exosomal transfer of p-STAT3 promotes acquired 5-FU resistance in colorectal cancer cells
Zhang, Q., Liu, R., Chan, K., Hu, J., Zhang, J., Wei, L., Tan, H., Yang, X., & Liu, H. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1314-9 · Cited by 142
Erdile, L. F., Heyer, W., Kolodner, R. D., & Kelly, T. J. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99069-1 · Cited by 140
Yamasaki, M., Makino, T., Masuzawa, T., Kurokawa, Y., Miyata, H., Takiguchi, S., Nakajima, K., Fujiwara, Y., Matsuura, N., Mori, M., et al. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606071 · Cited by 140
Joshi, M.-B. M., Shirota, Y., Danenberg, K. D., Conlon, D. H., Salonga, D. S., Herndon, J. E., Danenberg, P. V., & Harpole, D. H. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1387 · Cited by 138
Mitsuuchi, Y., Johnson, S. W., Selvakumaran, M., Williams, S. J., Hamilton, T. C., & Testa, J. R. (2000) · PubMed · Cited by 137
Jarhad, D. B., Mashelkar, K. K., Kim, H., Noh, M., & Jeong, L. S. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00185 · Cited by 136
EGFR-Targeted Therapy for Non-Small Cell Lung Cancer: Focus on EGFR Oncogenic Mutation
Antonicelli, A., Cafarotti, S., Indini, A., Galli, A., Russo, A., Cesario, A., Lococo, F., Russo, P., Mainini, A. F., Bonifati, L. G., et al. (2013) · International Journal of Medical Sciences · doi:10.7150/ijms.4609 · Cited by 134
Falasca, M. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210791033950 · Cited by 131
Liedert, B., Materna, V., Schadendorf, D., Thomale, J., & Lage, H. (2003) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2003.12313.x · Cited by 129
STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapy in vitro and in vivo
Spitzner, M., Roesler, B., Bielfeld, C., Emons, G., Gaedcke, J., Wolff, H. A., Rave‐Fränk, M., Kramer, F., Beissbarth, T., Kitz, J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28429 · Cited by 128
Branch, P., Masson, M., Aquilina, G., Bignami, M., & Karran, P. (2000) · Oncogene · doi:10.1038/sj.onc.1203668 · Cited by 126
Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells
You, Y., Zheng, Q., Dong, Y., Xie, X., Wang, Y., Wu, S., Zhang, L., Wang, Y., Xue, T., Wang, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8515 · Cited by 124
Desai, A. B., Webb, B. M., & Gerson, S. L. (2014) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2013.10.040 · Cited by 122
Cetuximab With Concurrent Chemoradiation for Esophagogastric Cancer: Assessment of Toxicity
Safran, H. P., Suntharalingam, M., DiPetrillo, T., Ng, T., Doyle, L. A., Krasna, M. J., Plette, A., Evans, D. L., Wanebo, H. J., Akerman, P., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.07.2325 · Cited by 119
Yu, L., Gu, C., Zhong, D., Shi, L., Kong, Y., Zhou, Z., & Liu, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.09.020 · Cited by 117
The role of copper transporters in the development of resistance to Pt drugs
Safaei, R., Holzer, A. K., Katano, K., Samimi, G., & Howell, S. B. (2004) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2004.05.006 · Cited by 114
Mellish, K. J., Kelland, L., & Harrap, K. R. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.322 · Cited by 113
Molecular mechanisms of cisplatin resistance in bladder cancer
Drayton, R. M., & Catto, J. W. F. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.11.201 · Cited by 112
Li, B., Xu, W., Lam, A. K.-Y., Wang, Y., Hu, H., Guan, X., Qin, Y., Saremi, N., Tsao, S. W., He, Q., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16333 · Cited by 112
Self-citationGlutaminase-1 (GLS1) inhibition limits metastatic progression in osteosarcoma
Ren, L., Ruiz‐Rodado, V., Dowdy, T., Huang, S., Issaq, S. H., Beck, J. A., Wang, H., Hoang, C. D., Lita, A., Larion, M., et al. (2020) · Cancer & Metabolism · doi:10.1186/s40170-020-0209-8 · Cited by 112
Bmi1 Enhances Tumorigenicity and Cancer Stem Cell Function in Pancreatic Adenocarcinoma
Proctor, E., Waghray, M., Lee, C. J., Heidt, D. G., Yalamanchili, M., Li, C., Bednar, F., & Simeone, D. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055820 · Cited by 111
Mechanisms of tumor resistance to EGFR-targeted therapies
Hopper-Borge, E. A., Nasto, R. E., Ratushny, V., Weiner, L. M., Golemis, E. A., & Astsaturov, I. A. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14712590902735795 · Cited by 109
Wakai (2010) · Oncology Reports · doi:10.3892/or_00000721 · Cited by 108
Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer
Hengstler, J. G., Lange, J., Kett, A., Dornhöfer, N., Meinert, R., Arand, M., Knapstein, P. G., Becker, R., Oesch, F., & Tanner, B. (1999) · PubMed · doi:10.5167/uzh-113865 · Cited by 106
Mader, R. M., Müller, M., & Steger, G. G. (1998) · General Pharmacology The Vascular System · doi:10.1016/s0306-3623(98)00191-8 · Cited by 104
Dysregulated Expression of FOXM1 Isoforms Drives Progression of Pancreatic Cancer
Kong, X., Li, L., Li, Z., Le, X., Huang, C., Jia, Z., Cui, J., Huang, S., Wang, L., & Xie, K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3859 · Cited by 103
Yano, T., Muto, M., Minashi, K., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27320 · Cited by 101
Wang, X., Jiang, P., Wang, P., Yang, C. S., Wang, X., & Feng, Q. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125402 · Cited by 100
Zhang, X., Komaki, R. K., Wang, L., Fang, B., & Chang, J. Y. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1528 · Cited by 99
Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation
Gurpinar, E., & Vousden, K. H. (2015) · Trends in Cell Biology · doi:10.1016/j.tcb.2015.04.001 · Cited by 98
Ahmed, K. M., Zhang, H., & Park, C. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3537 · Cited by 97
BMI-1, a promising therapeutic target for human cancer
Wang, M., Li, C., Cui, J., Jiao, M., Wu, T., Li, J., & Nan, K. (2015) · Oncology Letters · doi:10.3892/ol.2015.3361 · Cited by 96
Osimertinib (AZD9291)—a science-driven, collaborative approach to rapid drug design and development
Yver, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw129 · Cited by 96
Chen, G.-Z., Zhu, H., Dai, W., Zeng, X., Luo, J., & Sun, X.-C. (2017) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.03.23 · Cited by 93
ATM protein expression correlates with radioresistance in primary glioblastoma cells in culture
Tribius, S., Pidel, A., & Casper, D. (2001) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(01)01489-4 · Cited by 90
Stanley, A., Ashrafi, G. H., Seddon, A. M., & Modjtahedi, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-04301-8 · Cited by 89
Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response
Guarducci, C., Bonechi, M., Boccalini, G., Benelli, M., Risi, E., Leo, A. D., Malorni, L., & Migliaccio, I. (2017) · Breast Care · doi:10.1159/000484167 · Cited by 89
Copper transporter CTR1 expression and tissue platinum concentration in non-small cell lung cancer
Kim, E. S., Tang, X., Peterson, D. R., Kilari, D., Chow, C.-W. B., Fujimoto, J., Kalhor, N., Swisher, S. G., Stewart, D. J., Wistuba, I. I., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.04.005 · Cited by 88
STAT3 tyrosine phosphorylation influences survival in glioblastoma
Birner, P., Tumangelova-Yuzeir, K. D., Natchev, S., & Guentchev, M. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-010-0195-8 · Cited by 87
Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells
Shimura, T., Noma, N., Oikawa, T., Ochiai, Y., Kakuda, S., Kuwahara, Y., Takai, Y., Takahashi, A., & Fukumoto, M. (2012) · Oncogenesis · doi:10.1038/oncsis.2012.12 · Cited by 86
Can dihydropyrimidine dehydrogenase impact 5-fluorouracil-based treatment?
Milano, G. A., & McLeod, H. L. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(99)00211-7 · Cited by 86
Miyanishi, K., Takayama, T., Ohi, M., Hayashi, T., Nobuoka, A., Nakajima, T., Takimoto, R., Kogawa, K., Kato, J., Sakamaki, S., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.27982 · Cited by 86
Talazoparib Is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
Laird, J. H., Lok, B. H., Ma, J., Bell, A., de Stanchina, E., Poirier, J. T., & Rudin, C. M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0401 · Cited by 85
Peddi, P. F., & Hurvitz, S. A. (2014) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834014539183 · Cited by 84
Miyashita, H., Nitta, Y., Mori, S., Kanzaki, A., Nakayama, K., Terada, K., Sugiyama, T., Kawamura, H., Satō, A., MORIKAWA, H., et al. (2003) · Oral Oncology · doi:10.1016/s1368-8375(02)00038-6 · Cited by 83
Surowiak, P., Materna, V., Maciejczyk, A., Pudełko, M., Markwitz, E., Spaczyński, M., Dietel, M., Zabel, M., & Lage, H. (2007) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-006-0362-7 · Cited by 81
RPA Inhibition Increases Replication Stress and Suppresses Tumor Growth
Glanzer, J. G., Liu, S., Wang, L., Mosel, A., Peng, A., & Oakley, G. G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0306 · Cited by 80
Treatment options for esophageal squamous cell carcinoma
Nakajima, M., & Kato, H. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.801454 · Cited by 80
Li, X., Lin, Z., Zhang, B., Guo, L., Liu, S., Li, H., Zhang, J., & Ye, Q. (2016) · Scientific Reports · doi:10.1038/srep21010 · Cited by 79
Miragaya, J. G., Palafox, M., Paré, L., Yoldi, G., Ferrer, I., Vila, S., Galván, P., Pellegrini, P., Perez‐Montoyo, H., Igea, A., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2017.03.026 · Cited by 79
Wang, Z., Zhang, L., Ni, Z., Sun, J., Gao, H. Q., Cheng, Z., Xu, J., & Yin, P. (2015) · Tumor Biology · doi:10.1007/s13277-015-3636-3 · Cited by 77
Priller, M., Pöschl, J., Abrão, L., von Bueren, A. O., Cho, Y., Rutkowski, S., Kretzschmar, H. A., & Schüller, U. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1214 · Cited by 77
Li, B., Li, J., Xu, W., Guan, X., Qin, Y.-R., Zhang, L. Y., Law, S. Y.-K., Tsao, S. W., & Cheung, A. L. M. (2014) · Oncotarget · doi:10.18632/oncotarget.2596 · Cited by 76
Self-citationGadducci, A., Cosio, S., Muraca, S., & Genazzani, A. R. (2002) · PubMed · Cited by 75
Lu, Y., Wei, C., & Xi, Z. (2014) · In Vitro Cellular & Developmental Biology - Animal · doi:10.1007/s11626-014-9779-5 · Cited by 72
Chen, Y., Li, X., Guo, L., Wu, X., He, C., Zhang, S., Xiao, Y., Yang, Y., & Hao, D. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3623 · Cited by 72
Gasca, J., Flores, M. L., Jiménez‐Guerrero, R., Sáez, M. E., Barragán, I., Ruíz‐Borrego, M., Tortolero, M., Romero, F., Sáez, C., & Japón, M. Á. (2020) · Cell Death Discovery · doi:10.1038/s41420-020-00322-x · Cited by 72
Molecular Targets and Mechanisms of Radiosensitization Using DNA Damage Response Pathways
Raleigh, D. R., & Haas-Kogan, D. A. (2013) · Future Oncology · doi:10.2217/fon.12.185 · Cited by 71
Ribosomal S6 protein kinase 4 promotes radioresistance in esophageal squamous cell carcinoma
Li, M., Fan, L., Han, D., Yu, Z., Ma, J., Liu, Y.-X., Li, P., Zhao, D., Chai, J., Jiang, L., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci134930 · Cited by 71
Self-citationSpierings, D. C. J., de Vries, E. G. E., Vellenga, E., & de Jong, S. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401248 · Cited by 69
Nile, D. L., Rae, C. J., Hyndman, I., Gaze, M. N., & Mairs, R. J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2656-8 · Cited by 69
Aida, T., Takebayashi, Y., Shimizu, T., Okamura, C., Higasimoto, M., Kanzaki, A., Nakayama, K., Terada, K., Sugiyama, T., Miyazaki, K., et al. (2005) · Gynecologic Oncology · doi:10.1016/j.ygyno.2004.12.042 · Cited by 68
Li, B., Xu, W. W., Guan, X., Qin, Y., Law, S. Y.-K., Lee, N. P. Y., Chan, K. T., Tam, P. Y., Li, Y. Y., Chan, K. W., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1196 · Cited by 68
Self-citationChen, L., & Pan, J. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13836 · Cited by 66
Gomez‐Bougie, P., Bataille, R., & Amiot, M. (2005) · European Journal of Immunology · doi:10.1002/eji.200425878 · Cited by 65
Targeting tumor cells by enhancing radiation sensitivity
McKenna, W. G., & Muschel, R. J. (2003) · Genes Chromosomes and Cancer · doi:10.1002/gcc.10296 · Cited by 64
Prolonged autophagy by MTOR inhibitor leads radioresistant cancer cells into senescence
Nam, H. Y., Han, M. W., Chang, H. W., Kim, S. Y., & Kim, S. W. (2013) · Autophagy · doi:10.4161/auto.25879 · Cited by 62
Jin, Y., Chen, Q., Xu, K., Ren, H., Bao, X., Ma, Y., Wei, Y., & Ma, H. B. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2816-9 · Cited by 61
Hengstler, J. G., Pilch, H., Schmidt, M., Dahlenburg, H., Sagem�ller, J., Schiffer, I. B., Oesch, F., Knapstein, P. G., Kaina, B., & Tanner, B. (2001) · International Journal of Cancer · Cited by 60
Lan, X., Wu, Y., Wang, Y., Wu, F., Zang, C., TANG, C., Cao, S., & Li, S. (2012) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2012.1208 · Cited by 60
Sang, N., Severino, A., Russo, P., Baldi, A., Giordano, A., Mileo, A. M., Paggi, M. G., & Luca, A. D. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010346200 · Cited by 59
He, E., Pan, F., Li, G., & Li, J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0126149 · Cited by 58
Phosphatidylinositol 3-kinase related kinases
Abraham, R. T. (1996) · Current Opinion in Immunology · doi:10.1016/s0952-7915(96)80132-4 · Cited by 58
Bastos, L. G., de Marcondes, P. G., de‐Freitas‐Junior, J. C. M., Leve, F., Mencalha, A. L., de Souza, W. F., de Araújo, W. M., Tanaka, M. N., Abdelhay, E. S. F. W., & Morgado‐Díaz, J. A. (2014) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24896 · Cited by 57
Protein trafficking in response to DNA damage
Tembe, V., & Henderson, B. R. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.03.001 · Cited by 57
Outcomes after surgery for esophageal cancer.
D’Amico, T. A. (2007) · PubMed Central · Cited by 56
Quiescence and attenuated DNA damage response promote survival of esophageal cancer stem cells
Chen, Y., Li, D., Wang, D., Liu, X., Yin, N. B., Song, Y., Lu, S., Ju, Z., & Zhan, Q. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24228 · Cited by 56
Su, H., Jin, X., Zhang, X., Zhao, L., Lin, B., Li, L., Fei, Z., Shen, L., Fang, Y., Pan, H., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0464-6 · Cited by 56
Role of autophagy in resistance to oxaliplatin in hepatocellular carcinoma cells
Qiu, W. (2011) · Oncology Reports · doi:10.3892/or.2011.1464 · Cited by 55
Dmitriev, O. Y. (2011) · Biochemistry and Cell Biology · doi:10.1139/o10-150 · Cited by 55
Ismail, A., Bandla, S., Réveiller, M., Toia, L. M., Zhou, Z., Gooding, W. E., Kalatskaya, I., Stein, L. D., D’Souza, M., Litle, V. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0244 · Cited by 54
Bi, Y., Verginadis, I. I., Dey, S., Lin, L. L., Guo, L., Zheng, Y., & Koumenis, C. (2018) · Gynecologic Oncology · doi:10.1016/j.ygyno.2018.07.002 · Cited by 54
Otani, K., Naito, Y., Sakaguchi, Y., Seo, Y., Takahashi, Y., Kikuta, J., Ogawa, K., & Ishii, M. (2016) · Scientific Reports · doi:10.1038/srep30689 · Cited by 53
FU, Y., Ye, D., Chen, H., et al. (2007) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.10.061 · Cited by 52
Miyata, H., Doki, Y., YAMAMOTO, H. S., Kishi, K., Takemoto, H., Fujiwara, Y., Yasuda, T., Yano, M., Inoue, M., Shiozaki, H., et al. (2001) · PubMed · Cited by 52
Beclin1-induced Autophagy Abrogates Radioresistance of Lung Cancer Cells by Suppressing Osteopontin
Chang, S.-H., Minai‐Tehrani, A., Shin, J., Park, S. J., Kim, J., Yu, K., Hong, S., Hong, C., Lee, K.-H., Beck, G. R., et al. (2012) · Journal of Radiation Research · doi:10.1269/jrr.11148 · Cited by 52
Huang, C., Zhang, X., Jiang, L., Zhang, L., Xiang, M., & Ren, H. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.05.005 · Cited by 50
Radiation-induced DNA damage response and resistance in colorectal cancer stem-like cells
Anuja, K., Chowdhury, A. R., Saha, A., Roy, S., Rath, A. K., Kar, M., & Banerjee, B. (2019) · International Journal of Radiation Biology · doi:10.1080/09553002.2019.1580401 · Cited by 49
The radiosensitization effect of NS398 on esophageal cancer stem cell-like radioresistant cells
Che, S., Zhang, X.-Z., Liu, X., Chen, X., & Hou, L. (2010) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2010.01138.x · Cited by 47
Ogawa, R., Ishiguro, H., Kuwabara, Y., Kimura, M., Mitsui, A., Mori, Y., Mori, R., Tomoda, K., Katada, T., Harada, K., et al. (2007) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2007.00759.x · Cited by 47
Influence of XRCC1 Genetic Polymorphisms on Ionizing Radiation‐Induced DNA Damage and Repair
Sterpone, S., & Cozzi, R. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/780369 · Cited by 47
Liu, B., Wang, C., Chen, P., Cheng, B., & Cheng, Y. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s152818 · Cited by 47
Bian, L., Meng, Y., Zhang, M., Guo, Z., Liu, F.-R., Zhang, W., Xue, K., Su, Y., Wang, M., Yao Zong, Y. U. A. N., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.41246 · Cited by 47
Chen, Z.-T., Zhao, W., Qu, S., Li, L., LU, X.-D., Su, F., Liang, Z., GUO, S.-Y., & Zhu, X. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3604 · Cited by 46
Zou, Y., Hu, G., Zhao, X.-Q., Lu, T., Zhu, F., Yu, S., & Xiong, H. (2014) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-014-1349-2 · Cited by 46
Palm-Espling, M. E., Andersson, C. D., Björn, E., Linusson, A., & Wittung-Stafshede, P. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070473 · Cited by 46
Huang, W., Wu, S.-F., Xu, S., Ma, Y. C., Wang, R., Jin, S., & Zhou, S. (2020) · Journal of Food Science · doi:10.1111/1750-3841.15156 · Cited by 44
Inhibition of STAT3/cyclinD1 pathway promotes chemotherapeutic sensitivity of colorectal caner
Qin, A., Yu, Q., Gao, Y., Tan, J., Huang, H., Qiao, Z., & Qian, W. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.01.048 · Cited by 43
Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer
Fiúza, M. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0048-z · Cited by 43
Modi, S., Kir, D., Giri, B., Majumder, K., Arora, N., Dudeja, V., Banerjee, S., & Saluja, A. K. (2015) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-015-3000-3 · Cited by 42
Changes in survivin messenger RNA level during cisplatin treatment in gastric cancer
Ikeguchi, M., & Kaibara, N. (2001) · International Journal of Molecular Medicine · doi:10.3892/ijmm.8.6.661 · Cited by 42
Kim, C. W., Lu, J. N., Go, S., Jung, J. H., Yi, S. M., Jeong, J., Hah, Y., Han, M. S., Park, J. W., Lee, W. S., et al. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2070 · Cited by 42
Breast cancer stem cell-like cells generated during TGFβ-induced EMT are radioresistant
Konge, J. C., Leteurtre, F., Goislard, M., Biard, D. S. F., Altmeyer‐Morel, S., Vaurijoux, A., Gruel, G., Chevillard, S., & Lebeau, J. (2018) · Oncotarget · doi:10.18632/oncotarget.25240 · Cited by 42
Terraneo, N., Jacob, F., Peitzsch, C., Dubrovska, A., Krudewig, C., Huang, Y., Heinzelmann-Schwarz, V. A., Schibli, R., Béhé, M. P., & Grünberg, J. (2020) · Cancers · doi:10.3390/cancers12010217 · Cited by 42
Self-citationAlterations of oncogenes and tumor suppressor genes in esophageal cancer in China
Lu, S. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00023-5 · Cited by 40
Stark, T. W., Hensley, P. J., Spear, A., Pu, H., Strup, S. E., & Kyprianou, N. (2017) · The Prostate · doi:10.1002/pros.23435 · Cited by 39
Activation of PTGS2/NF‐κB signaling pathway enhances radiation resistance of glioma
Tan, C. Y., Liu, L., Liu, X., Qi, L., Wang, W., Zhao, G., Wang, L., & Dai, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.1971 · Cited by 38
Replication Protein A (RPA) Mediates Radio-Resistance of Glioblastoma Cancer Stem-Like Cells
Pedersen, H., Obara, E. A. A., Elbæk, K. J., Vitting‐Seerup, K., & Hamerlik, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051588 · Cited by 38
Li, L., Dong, H., Zhao, F., Tang, J., Chen, X., Ding, J., Men, H.-T., Luo, W.-X., Du, Y., Ge, J., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.12.013 · Cited by 37
Activation of the phosphorylation of ATM contributes to radioresistance of glioma stem cells
Zhou, W., Sun, M., Li, G., Wu, Y., WANG, Y., Jin, F., Zhang, Y., Yang, L., & Wang, D. (2013) · Oncology Reports · doi:10.3892/or.2013.2614 · Cited by 37
Camero, S., Ceccarelli, S., Felice, F. D., Marampon, F., Mannarino, O., Camicia, L., Vescarelli, E., Pontecorvi, P., Pizer, B. L., Shukla, R., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2774-6 · Cited by 37
Yamaguchi, N., Mimoto, R., Yanaihara, N., Imawari, Y., Hirooka, S., Okamoto, A., & Yoshida, K. (2015) · Tumor Biology · doi:10.1007/s13277-015-3264-y · Cited by 36
Fijołek, J., Wiatr, E., Rowinska-Zakrzewska, E., Giedronowicz, D., Langfort, R., Chabowski, M., Orlowski, T. M., & Roszkowski, K. (2006) · The International Journal of Biological Markers · doi:10.1177/172460080602100203 · Cited by 33
Taxanes: their impact on gynecologic malignancy
Schwab, C. L., English, D. P.-G., Roque, D. M., & Santin, A. D. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000057 · Cited by 33
Epithelial-mesenchymal transition in cancer: An overview
Ramos, F. S., Wons, L., Cavalli, I. J., & Ribeiro, E. M. S. F. (2017) · Integrative Cancer Science and Therapeutics · doi:10.15761/icst.1000243 · Cited by 33
Establishment and characterization of a paclitaxel-resistant human esophageal carcinoma cell line
Wang, C., Guo, L., Ma, J.-Y., Li, Y., & Liu, H. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.2083 · Cited by 32
Cited by
Mitochondrial Metabolism: A New Dimension of Personalized Oncology
Behnam, B., & Taghizadeh-Hesary, F. (2023) · Cancers · doi:10.3390/cancers15164058 · Cited by 44
MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation
Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30
Enhancing radiotherapy techniques for Triple-Negative breast cancer treatment
Sarlak, S., Pagès, G., & Luciano, F. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102939 · Cited by 19
Shiridokht, F., Kehtari, P., Eskandani, M., Farajollahi, A., & Vandghanooni, S. (2025) · International Journal of Pharmaceutics: X · doi:10.1016/j.ijpx.2025.100419 · Cited by 4
Metadata
- Authors
- Liu, Y., Zheng, C., Huang, Y., He, M., Xu, W. W., & Li, B.
- Venue
- MedComm
- Publisher
- Wiley
- Published
- 2021-06-10
- Volume
- 2
- Issue
- 3
- Pages
- 315-340
- ISSN
- 2688-2663 (ISSN-L)
- OpenAlex
- W3172453970
- Cited by
- 387
- References
- 227
- FWCI
- 18.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.